ENOVIS CORP (ENOV) Stock Fundamental Analysis
USA - NYSE:ENOV - US1940141062 - Common Stock
31.49 USD
+0.05 (+0.16%)
31.49 USD
0 (0%)
Overall ENOV gets a fundamental rating of 4 out of 10. We evaluated ENOV against 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ENOV have multiple concerns. ENOV has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ENOV was profitable.
In the past year ENOV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
1.2 Ratios
ENOV has a Return On Assets (-16.48%) which is comparable to the rest of the industry.
With a Return On Equity value of -32.10%, ENOV perfoms like the industry average, outperforming 53.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROIC | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ENOV has declined.
ENOV's Gross Margin of 56.32% is in line compared to the rest of the industry. ENOV outperforms 53.44% of its industry peers.
In the last couple of years the Gross Margin of ENOV has grown nicely.
ENOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
ENOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENOV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ENOV has more shares outstanding
Compared to 1 year ago, ENOV has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.94, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
ENOV's Altman-Z score of 0.94 is in line compared to the rest of the industry. ENOV outperforms 49.74% of its industry peers.
ENOV has a Debt/Equity ratio of 0.53. This is a neutral value indicating ENOV is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.53, ENOV is doing worse than 60.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.94 |
ROIC/WACCN/A
WACC7.35%
2.3 Liquidity
ENOV has a Current Ratio of 2.25. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
ENOV has a Current ratio (2.25) which is in line with its industry peers.
A Quick Ratio of 1.15 indicates that ENOV should not have too much problems paying its short term obligations.
The Quick ratio of ENOV (1.15) is worse than 70.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.01% over the past year.
ENOV shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -16.18% yearly.
The Revenue has grown by 14.40% in the past year. This is quite good.
Measured over the past years, ENOV shows a decrease in Revenue. The Revenue has been decreasing by -8.73% on average per year.
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
3.2 Future
Based on estimates for the next years, ENOV will show a very strong growth in Earnings Per Share. The EPS will grow by 23.19% on average per year.
The Revenue is expected to grow by 8.87% on average over the next years. This is quite good.
EPS Next Y12.58%
EPS Next 2Y12.38%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.51, the valuation of ENOV can be described as reasonable.
Based on the Price/Earnings ratio, ENOV is valued cheaper than 93.12% of the companies in the same industry.
When comparing the Price/Earnings ratio of ENOV to the average of the S&P500 Index (26.13), we can say ENOV is valued rather cheaply.
The Price/Forward Earnings ratio is 8.81, which indicates a very decent valuation of ENOV.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 96.30% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.35, ENOV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.51 | ||
| Fwd PE | 8.81 |
4.2 Price Multiples
87.30% of the companies in the same industry are more expensive than ENOV, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.12 |
4.3 Compensation for Growth
ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ENOV's earnings are expected to grow with 13.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.76
PEG (5Y)N/A
EPS Next 2Y12.38%
EPS Next 3Y13.12%
5. Dividend
5.1 Amount
No dividends for ENOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.49
+0.05 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners121.31%
Inst Owner Change-0.52%
Ins Owners1.19%
Ins Owner Change7.81%
Market Cap1.80B
Revenue(TTM)2.19B
Net Income(TTM)-827563000
Analysts83.53
Price Target52.79 (67.64%)
Short Float %12.75%
Short Ratio8.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.28%
Min EPS beat(2)6.8%
Max EPS beat(2)7.76%
EPS beat(4)4
Avg EPS beat(4)8.94%
Min EPS beat(4)4.97%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)5.78%
EPS beat(12)12
Avg EPS beat(12)8.75%
EPS beat(16)15
Avg EPS beat(16)7.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-0.21%
Revenue beat(4)0
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.21%
Revenue beat(8)2
Avg Revenue beat(8)-0.97%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-8.66%
PT rev (1m)-4.75%
PT rev (3m)-11.45%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)-1.65%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.89%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)0.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.51 | ||
| Fwd PE | 8.81 | ||
| P/S | 0.82 | ||
| P/FCF | N/A | ||
| P/OCF | 9.57 | ||
| P/B | 0.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.12 |
EPS(TTM)3.31
EY10.51%
EPS(NY)3.57
Fwd EY11.35%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)3.29
OCFY10.45%
SpS38.31
BVpS45.1
TBVpS-9.54
PEG (NY)0.76
PEG (5Y)N/A
Graham Number57.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score3
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 66.53% | ||
| Cap/Sales | 8.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 66.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 0.94 |
F-Score3
WACC7.35%
ROIC/WACCN/A
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
EPS Next Y12.58%
EPS Next 2Y12.38%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
EBIT growth 1Y-155.23%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year74.87%
EBIT Next 3Y29.81%
EBIT Next 5Y28.11%
FCF growth 1Y96.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y889.17%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%
ENOVIS CORP / ENOV FAQ
What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?
ChartMill assigns a fundamental rating of 4 / 10 to ENOV.
Can you provide the valuation status for ENOVIS CORP?
ChartMill assigns a valuation rating of 6 / 10 to ENOVIS CORP (ENOV). This can be considered as Fairly Valued.
Can you provide the profitability details for ENOVIS CORP?
ENOVIS CORP (ENOV) has a profitability rating of 3 / 10.
What is the earnings growth outlook for ENOVIS CORP?
The Earnings per Share (EPS) of ENOVIS CORP (ENOV) is expected to grow by 12.58% in the next year.